Clinical Trial Search

Primary: Mean Change From Baseline to Study Endpoint in the Aberrant Behavior Checklist (ABC) Irritability & Agitation Subscale Score. — -8.68; -6.05 score on a scale

Primary: Percent Change in Atheroma Volume (PAV) in the Thoracic Aorta of Spironolactone vs. Placebo — 0.5; 7.3 percentage change — p=0.0293

Primary: Usability — 79.3 score on a scale — p=0.001

Primary: Percent of Subjects' Study Eyes With Pupil Diameter Returning to Baseline — 142; 7; 102; 117 Participants

Primary: Percentage of Participants Screened as Eligible — 180 Participants

Primary: Sensitivity and Specificity, Based on Two Macula-centered Images (One Image From Each Eye of the Patient) — 92.98; 91.36 percentage of participants

Primary: Change in Baseline Cepstral/Spectral Index of Dysphonia (CSID) — 1.22; 4.45; 4.56; 3.13 score on a scale

Primary: Number of Visits to the Emergency Department by the Person With Dementia — 15 visits to the Emergency Department

Primary: Patient Preference — 14; 4; 2 Participants

Primary: Rate of Canine Retraction in mm Per Month — 5.38; 5.1 millimeters

Primary: The Percentage of Eligible and Contacted Patients Who Were Randomised Into the Trial — 100 Participants

Primary: Change in Ki-67 Expression Assessed in Tumor Tissue by Immunohistochemistry — 1.3 percentage of cells expressing Ki67

Primary: Overall Response Rate — 72; 35 Percentage of participants

Primary: Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 13 — 13.0; 7.5 percentage of participants

Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants